ES2192520T3 - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
ES2192520T3
ES2192520T3 ES00911011T ES00911011T ES2192520T3 ES 2192520 T3 ES2192520 T3 ES 2192520T3 ES 00911011 T ES00911011 T ES 00911011T ES 00911011 T ES00911011 T ES 00911011T ES 2192520 T3 ES2192520 T3 ES 2192520T3
Authority
ES
Spain
Prior art keywords
group
formula
alkyl
trifluoromethyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00911011T
Other languages
English (en)
Inventor
Thierry Gallet
Samir Jegham
Patrick Lardenois
Alistair Lochead
Alain Nedelec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2192520T3 publication Critical patent/ES2192520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Compuesto respondiendo a la fórmula general (I) **(Fórmula)** en la que X representa un átomo de oxígeno o un grupo de fórmula NZ en la que Z representa un átomo de hidrógeno o un grupo (C1-C5 )alquilo, n representa el número 0, 1 ó 2, y R1, R2, R3, R4 y R5 representan , cada uno, independientemente unos de otros, un átomo de hidrógeno o de halógeno o un grupo trifluorometilo, trifluorometoxi, ciano, hidroxi, (C1-C6 )alquilo eventualmente sustituido por un átomo de halógeno o un grupo trifluorometilo, ciano, hidroxi, (C1-C6) alquilo o (C1-C6) alcoxi o incluso también R2 y R3 forman en conjunto un grupo de fórmula -OCH2O- o -CH2-CH2CH2CH2-, en el estado de base o de sal de adición a un ácido.
ES00911011T 1999-03-30 2000-03-21 Composicion farmaceutica. Expired - Lifetime ES2192520T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9903934A FR2791678B1 (fr) 1999-03-30 1999-03-30 Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ES2192520T3 true ES2192520T3 (es) 2003-10-16

Family

ID=9543787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00911011T Expired - Lifetime ES2192520T3 (es) 1999-03-30 2000-03-21 Composicion farmaceutica.

Country Status (15)

Country Link
US (1) US6987106B1 (es)
EP (1) EP1165559B1 (es)
JP (1) JP4500454B2 (es)
AR (1) AR023188A1 (es)
AT (1) ATE232865T1 (es)
AU (1) AU3301800A (es)
CO (1) CO5180557A1 (es)
DE (1) DE60001451T2 (es)
DK (1) DK1165559T3 (es)
ES (1) ES2192520T3 (es)
FR (1) FR2791678B1 (es)
PE (1) PE20001600A1 (es)
TW (1) TWI221843B (es)
UY (1) UY26082A1 (es)
WO (1) WO2000058311A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1289996E (pt) 2000-05-25 2005-07-29 Targacept Inc Heteroarildiazabicicloalcanos como ligandos do receptor colinergico nicotinico
US6624167B1 (en) 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
ES2275808T3 (es) * 2001-02-06 2007-06-16 Pfizer Products Inc. Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
BR0314485A (pt) 2002-09-25 2005-07-26 Memory Pharm Corp Indazóis, benzotiazóis e benzoisotiazóis, composto, composição farmacêutica, método desativação/estimulação seletiva de receptores nicotìnicos de a-7 em um mamìfero e método de tratamento e/ou prevenção de uma doença com os mesmos
ATE445618T1 (de) * 2003-02-27 2009-10-15 Neurosearch As Neue diazabicyclische arylderivate
US20070244097A1 (en) * 2003-12-22 2007-10-18 Astrazeneca Ab Nicotinic AcetylcholineReceptor Ligands
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CA2550689A1 (en) 2003-12-22 2005-07-14 Memory Pharmaceuticals Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
JP2007520527A (ja) * 2004-02-04 2007-07-26 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
JP2007534692A (ja) 2004-04-22 2007-11-29 メモリー・ファーマシューティカルズ・コーポレイション インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用
KR20070015607A (ko) * 2004-05-07 2007-02-05 메모리 파마슈티칼스 코포레이션 1ｈ-인다졸, 벤조티아졸, 1,2-벤조이속사졸,1,2-벤조이소티아졸, 및 크로몬 및 그의 제조법 및 용도
US7652010B2 (en) * 2004-10-15 2010-01-26 Neurosearch A/S Azabicyclic aryl derivatives and their medical use
MX2007007328A (es) 2004-12-22 2007-07-25 Memory Pharm Corp Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos.
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
WO2007093600A1 (en) * 2006-02-14 2007-08-23 Neurosearch A/S Novel diazabicycloalkane derivatives and their medical use
JP2007217370A (ja) * 2006-02-17 2007-08-30 Nard Inst Ltd ポジトロン断層撮影法および該方法に用いるポジトロン放出化合物
WO2007135120A1 (en) 2006-05-23 2007-11-29 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
EP2083921A2 (en) 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
WO2008119710A1 (en) * 2007-03-30 2008-10-09 Neurosearch A/S Two-phase test method for characterizing the effect of a chemical compound on a test animal and maze for carrying out the method
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
FR2931823B1 (fr) * 2008-06-02 2012-08-17 Sanofi Aventis Sel de fumarate du 1,4-diazabicyclo°3.2.2!nonane-carboxylate de 4-bromophenyle, ses formes cristallines, leur preparation et leur utilisation en therapeutique
PT2540297E (pt) 2008-11-19 2015-08-26 Forum Pharmaceuticals Inc Tratamento de distúrbios cognitivos com (r)-7-cloro-n- (quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmaceuticamente aceitáveis desta
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
SA111320455B1 (ar) 2010-05-17 2014-10-16 Envivo Pharmaceuticals Inc صورة بلورية من (R)-7- كلورو -N- (كينوكليدين -3- يل) بنزو[b] ثيوفين -2- كربوكساميد هيدروكلوريد أحادي الهيدرات
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235878A3 (en) * 1986-01-16 1989-06-14 Beecham Group Plc Novel compounds
JP2668670B2 (ja) * 1995-03-24 1997-10-27 日本たばこ産業株式会社 ジアザビシクロ［３．３．１］ノナン誘導体、その中間体及びその医薬用途
DE69822300T2 (de) * 1997-06-30 2005-03-10 Targacept, Inc. 3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen

Also Published As

Publication number Publication date
US6987106B1 (en) 2006-01-17
ATE232865T1 (de) 2003-03-15
CO5180557A1 (es) 2002-07-30
JP2002540208A (ja) 2002-11-26
EP1165559A1 (fr) 2002-01-02
FR2791678B1 (fr) 2001-05-04
FR2791678A1 (fr) 2000-10-06
DK1165559T3 (da) 2003-06-10
TWI221843B (en) 2004-10-11
AU3301800A (en) 2000-10-16
UY26082A1 (es) 2000-10-31
PE20001600A1 (es) 2001-04-01
JP4500454B2 (ja) 2010-07-14
DE60001451D1 (de) 2003-03-27
DE60001451T2 (de) 2004-01-15
EP1165559B1 (fr) 2003-02-19
AR023188A1 (es) 2002-09-04
WO2000058311A1 (fr) 2000-10-05

Similar Documents

Publication Publication Date Title
ES2192520T3 (es) Composicion farmaceutica.
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
AR052915A1 (es) Derivados de pirrolidin y piperidin acetileno
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
ECSP10010006A (es) Derivado de oxopirazina y herbicida
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
MXPA04002647A (es) Antranilamidas artropodicidas.
NI201000130A (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica.
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
MEP7808A (en) Process for preparing 4-trifluoromethylsulphinylpyrazole derivative
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica
CO5601030A2 (es) Derivados de quinolinona/benzoxazinona y usos de los mismos
ECSP045078A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
ES2054309T3 (es) Compuestos de urea sustituida y su preparacion y uso.
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
CO5580721A2 (es) Composicion fungicida basada en al menos un derivado de piridilmetilbenzamida y al menos un derivado de ditiocarbamato
CO6331306A2 (es) Derivados de n-heterociclico-imidazo[1,2alfa]piridina-2-carboxamidas su preparacion y su aplicacion en terapeutica
DK1325923T3 (da) Cephem-forbindelser og ESBL-detekterende reagenser indeholdende disse
CO4940417A1 (es) DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
DE60115080D1 (de) Verfahren zur herstellung von bis-benzazolyl verbindungen
CO4890850A1 (es) Derivados de 6-pirrolidin-2-ilpiridinas, su reparacion y preparacion en terapeutica.